title: Novel quercetin glycosides as potent anti-MRSA and anti-VRE agents.
abstract: Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of these infections (Threat report 2013). Vancomycin is an FDA approved antibiotic and is growing importance in the treatment of hospital infections, with particular emphasis on its value to fight against methicillin-resistant Staphylococcus aureus (MRSA). The increasing use of vancomycin to treat infections caused by the Gram-positive MRSA in the 1970s selected for drug-resistant enterococci, less potent than staphylococci but opportunistic in the space vacated by other bacteria and in patients with compromised immune systems. The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the need for completely novel classes of antibacterial agents. This paper reports the recent patent review on the strategy for finding novel quercetinglycoside type antibacterial agents against vancomycin-resistant bacterial strains.
authors: Abugafar M L
authors: AM
authors: Hossion
authors: The University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA 15218, USA. chem.lokman@gmail.com.
authors: Kenji
authors: K
authors: Sasaki
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006027:Glycosides / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D010330:Patents as Topic; D011794:Quercetin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000627:therapeutic use*; D065507:Vancomycin-Resistant Enterococci
chemical_list: D000900:Anti-Bacterial Agents; D006027:Glycosides; D014640:Vancomycin; D011794:Quercetin